re ignited

A detailed plan for carrying out the trial was prepared and presented to potential partners.

Interest in licensing ATC was re-ignited and has been pursued.

Data from the clinical trial also showed that ATC was especially effective when used with particular other HIV drugs, and two new patents were filed covering these combinations.

As a result, there has been renewed interest from potential partners.


Revenue from ordinary activities $901,000
Net profit / (loss) for the period attributable to
members $1,562,000
Net tangible assets 20,962 in $A’000= $21M
Net tangible assets per ordinary security 2.5 Cents

current market cap = $25M
current market value of IP (3.0-2.5)cps=0.5 cps times 850M shares= $4M !!!

Time to burn NTA 13.5 years
Time to partner imminent

ps not mentioning the 1st generation integrase in China with 'cost of goods' competitive advantage, the 2nd generation integrase as the only once daily, non-boosted integrase inhibitor active against INI resistance, or the Valevia $65M anti bac that is being expanding testing cause its going so well...